vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Northfield Bancorp, Inc. (NFBK). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $41.3M, roughly 1.8× Northfield Bancorp, Inc.). On growth, Northfield Bancorp, Inc. posted the faster year-over-year revenue change (12.7% vs -36.9%). Northfield Bancorp, Inc. produced more free cash flow last quarter ($52.5M vs $-6.6M). Over the past eight quarters, Northfield Bancorp, Inc.'s revenue compounded faster (15.0% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Northfield Bancorp, Inc. is a regional bank holding company based in the United States, operating primarily across the U.S. Northeast region. It provides a full range of personal and commercial banking services including deposit accounts, mortgage loans, commercial lending, and wealth management solutions for retail consumers, small to medium-sized businesses and local community clients.

MED vs NFBK — Head-to-Head

Bigger by revenue
MED
MED
1.8× larger
MED
$75.1M
$41.3M
NFBK
Growing faster (revenue YoY)
NFBK
NFBK
+49.6% gap
NFBK
12.7%
-36.9%
MED
More free cash flow
NFBK
NFBK
$59.2M more FCF
NFBK
$52.5M
$-6.6M
MED
Faster 2-yr revenue CAGR
NFBK
NFBK
Annualised
NFBK
15.0%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
NFBK
NFBK
Revenue
$75.1M
$41.3M
Net Profit
$-27.4M
Gross Margin
69.4%
Operating Margin
-10.4%
-1263.3%
Net Margin
-1545.5%
Revenue YoY
-36.9%
12.7%
Net Profit YoY
-343.6%
EPS (diluted)
$-1.64
$-0.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
NFBK
NFBK
Q4 25
$75.1M
$41.3M
Q3 25
$89.4M
$39.2M
Q2 25
$105.6M
$38.9M
Q1 25
$115.7M
$34.8M
Q4 24
$119.0M
$36.7M
Q3 24
$140.2M
$31.8M
Q2 24
$168.6M
$31.5M
Q1 24
$174.7M
$31.3M
Net Profit
MED
MED
NFBK
NFBK
Q4 25
$-27.4M
Q3 25
$-2.3M
$10.8M
Q2 25
$2.5M
$9.6M
Q1 25
$-772.0K
$7.9M
Q4 24
$11.3M
Q3 24
$1.1M
$6.5M
Q2 24
$-8.2M
$6.0M
Q1 24
$8.3M
$6.2M
Gross Margin
MED
MED
NFBK
NFBK
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
MED
MED
NFBK
NFBK
Q4 25
-10.4%
-1263.3%
Q3 25
-4.6%
37.7%
Q2 25
-1.0%
35.6%
Q1 25
-1.1%
31.0%
Q4 24
0.6%
38.0%
Q3 24
1.5%
27.9%
Q2 24
-4.7%
29.1%
Q1 24
4.5%
27.2%
Net Margin
MED
MED
NFBK
NFBK
Q4 25
-1545.5%
Q3 25
-2.5%
27.4%
Q2 25
2.3%
24.6%
Q1 25
-0.7%
22.6%
Q4 24
30.7%
Q3 24
0.8%
20.5%
Q2 24
-4.8%
18.9%
Q1 24
4.8%
19.9%
EPS (diluted)
MED
MED
NFBK
NFBK
Q4 25
$-1.64
$-0.68
Q3 25
$-0.21
$0.27
Q2 25
$0.22
$0.24
Q1 25
$-0.07
$0.19
Q4 24
$0.08
$0.27
Q3 24
$0.10
$0.16
Q2 24
$-0.75
$0.14
Q1 24
$0.76
$0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
NFBK
NFBK
Cash + ST InvestmentsLiquidity on hand
$167.3M
$164.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$690.1M
Total Assets
$248.0M
$5.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
NFBK
NFBK
Q4 25
$167.3M
$164.0M
Q3 25
$173.5M
$131.7M
Q2 25
$162.7M
$97.6M
Q1 25
$164.6M
$101.7M
Q4 24
$162.3M
$167.7M
Q3 24
$170.0M
$232.9M
Q2 24
$163.5M
$153.5M
Q1 24
$156.4M
$238.8M
Total Debt
MED
MED
NFBK
NFBK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$666.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
MED
MED
NFBK
NFBK
Q4 25
$198.9M
$690.1M
Q3 25
$214.7M
$719.6M
Q2 25
$216.0M
$710.3M
Q1 25
$211.0M
$711.1M
Q4 24
$210.1M
$704.7M
Q3 24
$207.3M
$699.6M
Q2 24
$205.3M
$693.0M
Q1 24
$211.0M
$698.4M
Total Assets
MED
MED
NFBK
NFBK
Q4 25
$248.0M
$5.8B
Q3 25
$268.2M
$5.7B
Q2 25
$269.3M
$5.7B
Q1 25
$280.0M
$5.7B
Q4 24
$284.2M
$5.7B
Q3 24
$291.2M
$5.7B
Q2 24
$293.5M
$5.7B
Q1 24
$302.8M
$5.9B
Debt / Equity
MED
MED
NFBK
NFBK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.95×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
NFBK
NFBK
Operating Cash FlowLast quarter
$-5.3M
$53.7M
Free Cash FlowOCF − Capex
$-6.6M
$52.5M
FCF MarginFCF / Revenue
-8.8%
127.1%
Capex IntensityCapex / Revenue
1.8%
2.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$89.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
NFBK
NFBK
Q4 25
$-5.3M
$53.7M
Q3 25
$12.1M
$13.9M
Q2 25
$-3.4M
$14.1M
Q1 25
$3.4M
$9.4M
Q4 24
$-4.9M
$31.1M
Q3 24
$9.1M
$14.0M
Q2 24
$13.1M
$6.9M
Q1 24
$7.3M
$4.2M
Free Cash Flow
MED
MED
NFBK
NFBK
Q4 25
$-6.6M
$52.5M
Q3 25
$10.8M
$13.6M
Q2 25
$-4.8M
$13.9M
Q1 25
$1.9M
$9.2M
Q4 24
$-7.2M
$30.0M
Q3 24
$7.7M
$13.7M
Q2 24
$11.1M
$6.7M
Q1 24
$5.4M
$3.8M
FCF Margin
MED
MED
NFBK
NFBK
Q4 25
-8.8%
127.1%
Q3 25
12.0%
34.6%
Q2 25
-4.5%
35.7%
Q1 25
1.6%
26.3%
Q4 24
-6.1%
81.6%
Q3 24
5.5%
43.2%
Q2 24
6.6%
21.1%
Q1 24
3.1%
12.1%
Capex Intensity
MED
MED
NFBK
NFBK
Q4 25
1.8%
2.8%
Q3 25
1.5%
0.8%
Q2 25
1.3%
0.6%
Q1 25
1.3%
0.7%
Q4 24
1.9%
3.1%
Q3 24
1.0%
0.7%
Q2 24
1.1%
0.8%
Q1 24
1.1%
1.4%
Cash Conversion
MED
MED
NFBK
NFBK
Q4 25
Q3 25
1.29×
Q2 25
-1.36×
1.48×
Q1 25
1.20×
Q4 24
2.76×
Q3 24
8.04×
2.14×
Q2 24
1.16×
Q1 24
0.88×
0.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons